RCS - Cambridge Cognition - Alzheimer’s Disease Validation for NeuroVocalix

Cambridge Cognition HoldingsAnnouncement

17/08/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220817:nRSQ2394Wa&default-theme=true

RNS Number : 2394W  Cambridge Cognition Holdings PLC  17 August 2022

 

Cambridge Cognition Holdings Plc

("Cambridge Cognition" or the "Company")

 

Cambridge Cognition selected by the University of Oxford

as a cognitive assessment partner for the ISAP study

 

Alzheimer's Disease Validation for NeuroVocalix(TM)( )

 

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets
digital solutions to assess brain health, is pleased to announce that it will
be collaborating with the University of Oxford by providing cognitive
assessments for the Impact of Semaglutide in Amyloid Positivity ("ISAP")
study. As a consequence Cambridge Cognition expects to receive validation data
for its voice-based solution, NeuroVocalixTM. The randomised controlled
trial, sponsored by the University of Oxford and funded by Novo Nordisk, aims
to investigate the effectiveness of a diabetes medication (oral semaglutide)
against the neuropathophysiology of Alzheimer's disease (specifically, tau
accumulation and neuroinflammation).

 

Alzheimer's disease is characterised by the abnormal build-up of amyloid and
tau proteins in the brain(1), which can occur years before clinical symptoms
such as memory loss are detected. More than 57.4 million people worldwide are
living with dementia and, without new therapeutics to slow or halt disease
progression, this number is expected to grow to 152.8 million by 2050(2). To
assess the potential for a new therapeutic approach, the University of Oxford
has launched the ISAP study.

 

The ISAP study will focus on developing a treatment for the earliest signs of
Alzheimer's disease by recruiting participants who are at increased risk of
developing dementia. Semaglutide is a diabetes medication that animal studies
suggest could reduce phospho-tau accumulation and improve cognitive
function(3). The ISAP study will track whether semaglutide can reduce
participants' tau pathology and neuroinflammation over the course of a year by
repeating MRI and PET imaging at the start of the study and 52 weeks. To
accurately assess cognitive change, participants will be asked to perform
Cambridge Cognition's digital assessments, CANTAB(TM) and NeuroVocalix(TM), at
the start of the study, week 26 and week 52.

 

This trial will combine both touchscreen and voice-based cognitive assessments
to track the earliest signs of dementia and the extent to which semaglutide
can slow or halt disease progression. The University of Oxford has selected
Cambridge Cognition as a cognitive assessment partner for this trial because
the company offers several sensitive measures of cognitive processes that are
compromised in early Alzheimer's disease.

 

To find out more about the ISAP study, please visit the University of Oxford
website: https://www.dtu.ox.ac.uk/ISAP/ (https://www.dtu.ox.ac.uk/ISAP/)

 

Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

"We are delighted to be partnering with the University of Oxford to develop
better treatments for Alzheimer's disease. We are particularly pleased to be
including our voice solution, NeuroVocalix™, as we believe it could help
track the earliest cognitive indicators of dementia and this study is an
important step as we gather further validation data.  We have seen strong
early uptake of NeuroVocalix™ following launch to the academic community
last year and more than 20 institutions are using it."

 

Ivan Koychev, Chief Investigator of ISAP, said:

"The ISAP study paves the way for novel and much needed therapies for
Alzheimer's disease. Glucagon-like peptide-1 receptor agonist medications such
as semaglutide are particularly promising given the emerging evidence of
reduced dementia incidence in patients who take them as part of their diabetes
treatment. We are grateful to our commercial partners Novo Nordisk and
Cambridge Cognition for their support of this study."

 

References

1.    https://www.nhs.uk/conditions/alzheimers-disease/causes/
(https://www.nhs.uk/conditions/alzheimers-disease/causes/)

2.    https://www.alzheimers.org.uk/about-us/news-and-media/facts-media
(https://www.alzheimers.org.uk/about-us/news-and-media/facts-media)

3.
https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=39097
(https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=39097)

 

For further information, contact:

 

 Cambridge Cognition Holdings Plc                      Tel: 012 2381 0700

 Matthew Stork, Chief Executive Officer                press@camcog.com (mailto:press@camcog.com)

 Stephen Symonds, Chief Financial Officer
 Panmure Gordon (UK) Limited (NOMAD and Joint Broker)  Tel: 020 7886 2968

 Freddy Crossley / Emma Earl                           (Corporate Finance)

 Rupert Dearden                                        (Corporate Broking)
 Dowgate Capital Limited (Joint Broker)                Tel: 020 3903 7715

 David Poutney / James Serjeant
 IFC Advisory Ltd (Financial PR and IR)                Tel: 020 3934 6630

 Tim Metcalfe / Graham Herring / Zach Cohen

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company developing digital health products
to better understand, detect and treat conditions affecting brain health. The
Company's software products assess cognitive health in patients worldwide to
improve clinical trial outcomes, identify and stratify patients early and
improve global efficiency in pharmaceutical and healthcare industries.

 

For further information visit www.cambridgecognition.com
(http://www.cambridgecognition.com)

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABIGDIGGBDGDL